The decision by the National Health Service-England (NHSE) to cull 16 drugs from the U.K.’s Cancer Drugs Fund on clinical- and cost-effectiveness grounds has triggered fresh calls for it to be scrapped and replaced by a long-term, viable alternative.
The Association of the British Pharmaceutical Industry (ABPI) has expressed dismay at NHSE’s move, claiming that the only way to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?